Loading…
Laboratory confirmation of congenital rubella syndrome in South Korea in 2017: A genomic epidemiological investigation
•Endemic rubella has been eliminated in South Korea since 2011.•A case of suspected congenital rubella syndrome (CRS) was reported in 2017.•CRS was confirmed via rubella-specific IgM and RNA in urine and a throat swab.•Rubella virus, genotype 2b of Vietnamese origin was isolated in a throat swab.•La...
Saved in:
Published in: | Vaccine 2020-10, Vol.38 (44), p.6868-6871 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •Endemic rubella has been eliminated in South Korea since 2011.•A case of suspected congenital rubella syndrome (CRS) was reported in 2017.•CRS was confirmed via rubella-specific IgM and RNA in urine and a throat swab.•Rubella virus, genotype 2b of Vietnamese origin was isolated in a throat swab.•Laboratory surveillance is critical to rubella elimination.
The WHO Regional Verification Commission certified in 2017 that Korea was the first country in the WHO Western Pacific Region to achieve rubella elimination. A suspected congenital rubella syndrome (CRS) was reported to the Korea Centers for Disease Control and Prevention in August 2017. The mother of a new-born had visited Vietnam during her pregnancy. CRS was confirmed based on the detection of rubella-specific IgM and rubella RNA in the urine and throat swab. Rubella virus isolated from the throat swab was classified as genotype 2B, and a phylogenetic analysis indicated that this genotype had been imported from Vietnam. This is the first report of CRS confirmed using virus isolation in Korea. Laboratory surveillance plays a critical role in the elimination of rubella through the provision of laboratory testing data, and characterisation of circulating strains. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2020.08.064 |